IPO bound? Five years in, Art Krieg and the Checkmate crew collect $85M to back up their 1-drug pipeline
Five years after Art Krieg picked up a drug to make a bid in the feverish immuno-oncology space with a startup called Checkmate Pharmaceuticals, he and the team are still locked in to their single pathway approach. And they just scored $85 million and a couple of new marquee investments to make some important mid-stage moves on the R&D board.
The drug is CMP-001, which contains a CpG-A oligonucleotide that activates the TLR9 pathway to kick up an innate immune response to cancer — one of the most popular research strategies in the oncology handbook these days. And Checkmate says they are still the only player in biotech to go after this particular pathway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.